Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + lenvatinib + tislelizumab for unresectable hepatocellular carcinoma
ChiCTR2200064384Phase 3Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lenvatinib and tislelizumab in hepatocellular carcinoma (HCC), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: objective response rate. Started Oct 2022; status: recruiting.
02
Drugs
lenvatinibtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200064384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064384.